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Background: Chronic arthritis is a common feature of juvenile idiopathic arthritis (JIA) and systemic lupus
erythematosus (SLE). It was subsequently discovered that Toll-like receptors (TLRs) are able to upregulate cytokine
production in response to endogenous ligands released after tissue damage, suggesting that TLRs can maintain an
inflammatory response even in absence of pathogen. Thus, TLRs may contribute to increased inflammation in JIA
and SLE patients. The aim of this study was to investigate the role of TLRs in JIA and SLE. We examined the in vivo
expression and polymorphisms of TLR2 and TLR4 in peripheral monocytes of patients with JIA and SLE during
active and inactive disease phases.
Methods: This single center cohort study consisted of JIA and SLE affected children and control subjects. TLR2 and
TLR4 protein expression on CD14+ monocytes was examined by flow cytometry. TLR2 and TLR4 genotypes were
determined using the polymerase chain reaction-restriction fragment length polymorphism method (RFLP-PCR).
Results: A significant reduction in the level of TLR4 expression (p≤ 0.001) was observed on monocytes of patients
with JIA and SLE compared with that of healthy control subjects. There was no correlation between the TLR2 or
TLR4 genotypes and the observed differential TLR protein expression on monocytes.
Conclusions: To conclude, our observations suggest involvement of investigated TLRs in the pathogenesis of JIA
and SLE. It still remains to be elucidated whether reduced TLR4 expression is cause of chronic arthritis or a result of
some feedback loop.
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JIA refers to a group of chronic childhood arthropathies
of unknown aetiology. SLE is the prototypic systemic
autoimmune disease and is characterized by B cell
hyperreactivity and the production of autoantibodies [1].
Chronic arthritis, a common feature of JIA and SLE, in
the past was mainly attributed to dysregulated tolerance
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reproduction in any medium, provided the orT-cells. However, the innate immune system has an im-
portant role in the pathogenesis of arthritis. Toll-like
receptors (TLRs) are a key link between infection, inju-
ry and inflammation [2]. They recognize pathogen-
and danger-associated molecular patterns (PAMPs and
DAMPs), and subsequently trigger a pro-inflammatory
cascade, which induces the transcription of multiple
proinflammatory cytokine genes as well as dendritic cell
maturation [3,4]. Cell wall components of various Gram-
positive and Gram-negative pathogens, stress proteins and
cell decomposition products are predominantly identified
by the Toll-like receptors 2 and 4 [3,5]. Although TLR-
mediated inflammation is an important aspect of hostl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immune diseases, like rheumatoid arthritis (RA) and SLE
[4,6-9]. Feedback loops between DAMPS, PAMPs and their
overlapping receptors may link infectious triggers and disease
flares [10]. Self-molecules, (e.g. S100 proteins) indicating syn-
ovial tissue damage amplify inflammatory arthritis [11]. Serum
concentrations of S100A8/S100A9 proteins correlate well with
the disease activity in children [12]. Some studies suggest that
patients with clinically inactive JIA, but elevated levels of
S100A proteins, may be at risk for disease flares [13]. Children
with systemic onset of JIA show up to 20-fold higher S100A
serum protein concentrations than those found in other in-
flammatory disorders. In SLE elevated serum concentrations
also correlate significantly with disease activity index [14]. The
elevated expression levels of Toll-like receptors 2, TLR3 and
TLR4 have already been associated with the chronic joint in-
flammation in adult RA patients [15,16].
Associations between different polymorphisms within the
TLR2 and TLR4 genes or within the promoter region of the
TLR9 gene and susceptibility for RA and SLE are subjects of
great controversy [17-19]. Few studies exist to date on the
importance of innate immunity and of, in particular, Toll-
like receptors in the pathogenesis of JIA and SLE. Recently,
two common cosegregating missense mutations, Asp299Gly
and Thr399Ile, affecting the extracellular domain of the
TLR4 protein, have been characterized [20]. Both mutations
lead to an attenuated efficacy of lipopolysaccharide signaling
and a reduced capacity to elicit inflammation. Also for the
TLR2 gene two SNPs (Arg677Trp and Arg753Gln) have
been identified that abrogate the ability of TLR2 to mediate
a response to bacterial cell wall components [21].
DAMPS are found in high concentrations in inflamed
tissue, where neutrophils and monocytes belong to the
most abundant cell types. We hypothesized that the en-
during local inflammation triggered by DAMPS may cor-
relate with levels of TLR protein expression on CD14+
monocytes. We therefore decided to investigate the TLR2
and TLR4 protein expression on CD14+ monocytes of JIA
and pediatric SLE patients during active and inactive dis-
ease phases as well as the TLR expression levels of healthy
individuals. Furthermore we hypothesized that the two
single nucleotide polymorphisms (SNPs) of TLR2-gene
(Arg677Trp and Arg753Gln) and TLR4-gene (Asp299Gly
and Thr399Ile) are implicated in the pathogenesis of JIA
and SLE. The current study compared the allele frequency
and genotype distribution for these mutations among JIA
respectively SLE patients and healthy control subjects.
Methods
Patients and samples
This single center cohort study consisted of JIA and SLE
affected children and control subjects and was conducted
in the period 2008–2010. All JIA patients fit the ILAR
classification criteria for childhood arthritis and providedwritten informed consent before enrolment. SLE patients
who satisfied ECLAM criteria were enrolled in the study.
Peripheral venous blood was drawn from 76 patients of
our pediatric rheumatological outpatient clinic and from
67 similar gender non-related young adults to serve as
healthy controls. The study protocol was approved by the
institutional ethics committee (#837.169.08).
Patient demographics
Sixty-five JIA patients were enrolled after consent: 19 pa-
tients with systemic JIA (3 children under flare), 28 pa-
tients with oligoarthritis (3 children under flare), 9 patients
with seronegative polyarthritis (3 children under flare) and
11 patients with enthesitis related arthritis (3 children
under flare). Furthermore we enrolled 9 SLE patients (1 pa-
tient under flare). Comprehensive clinical information was
collected at each JIA patient visit, including history, phys-
ical examination (including presence of fever, rash and
joint count), and clinical laboratory values [erythrocyte
sedimentation rate (ESR), and C-reactive protein (CRP)].
Clinical status at each visit was graded according to a scor-
ing system developed by our group to grade severity of sys-
temic disease manifestations or arthritis. Each sample was
classified as “flare” (active disease; score of 5 or above) or
“quiescence” (inactive disease; score of 0). All patients were
under antiphlogistic (Naproxene) and/or immunosuppres-
sive (Methotrexate, Cyclosporin A, Azathioprin, steroids)
therapy, dependent upon their JIA subtype. Characteristics
of the study subjects are shown in Table 1.
Flow cytometry for detection of TLR2- and TLR4-surface
expression
Two-colour flow cytometry was applied to freshly iso-
lated whole blood samples, to investigate the expression
levels of TLR2 and TLR4 on peripheral blood monocytes
of JIA and SLE patients and healthy control subjects. For
surface staining 100 μl of whole blood samples were in-
cubated with the following anti-human primary anti-
bodies for 15 minutes in the dark at 4°C: anti-CD14
monoclonal antibody (mAb; 10 μl per 100 μl blood,
FITC or PE labelled, clone 8 G3; Diaclone, Besançon,
France), anti-TLR2 mAb (10 μl, FITC labelled, clone
HTA 125; eBioscience, San Diego, CA) or TLR4 mAb
(10 μl, PE labelled, clone HTA 125; eBioscience, San
Diego, CA). Isotype-matched antibody controls were
used to detect non-specific staining (Mouse IgG2a
Isotype Control, FITC or PE labelled; eBioscience, San
Diego, CA). Subsequently, red blood cells were lysed
with lysing solution (FACS; BD Biosciences) and re-
moved by washing two times with cell wash solution
(FACS; BD Biosciences). The immunostained cells were
fixed with 0.5% paraformaldehyde. Monocytes were
identified and gated according to their characteristic
forward- and side-scatter flow cytometry profiles and
Table 1 Patient demographics
Flow cytometry (TLR) RFLP (TLR)
Number of samples analyzed
patients/controls
76:67 76:67
Age at enrollment 13.4 (0–26) 13.4 (0–26)
[median (range) years]
Age at onset 6.3 (0–12) 6.3 (0–12)
[median (range) years]
Disease duration 4.7 (1–11) 4.7 (1–11)
[median (range) years]
Disease activity
No or low activity [n] 63 63
High activity/flare [n] 13 13
ESR (mm/h) 19 (0–103) 19 (0–103)
CRP (mg/l) 15 (1–372) 15 (1–372)
Male/female 26:50 26:50
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cytometer (FACSCalibur, Becton Dickinson) was used
for data acquisition. Routinely, 8.0 x 103 CD14+ cells
were counted. Flow cytometry data were analyzed by
using CellQuest software (version 5.3 for Macintosh; BD
Bioscience Immunocytometry Systems, San Jose, CA).
Mean channel fluorescence intensity (MFI) derived from
fluorescence histogram was used to study the level of
cell surface TLR expression. Delta MFI (dMFI) was cal-
culated as a subtraction and recorded as the MFI of the
TLR2 or TLR4 antibody minus the MFI of the isotype-
matched control antibody.
Genotyping of Toll-like receptor-2 and −4 genes
Genomic DNA was isolated from whole blood samples
using ZR Genomic DNA II Kit (Zymo Research, Irvine,
CA). Determination of the TLR 2 and 4 gene mutations
was accomplished with polymerase chain reaction (PCR)
and restriction fragment length polymorphism. Specific-
ally designed PCR primers were used to amplify a region
of the TLR2 and TLR4 gene spanning the respective sin-
gle nucleotide polymorphism (SNP). The primer se-
quences are presented in Table 2.
The total volume of the PCR was 25 μl containing
50 ng of genomic DNA, 1x PCR-buffer (Qiagen, Hilden,
Germany), 0.1 mM of each dNTP (Promega, Mannheim,
Germany), 1 unit of HotStar-TaqW DNA polymerase
(Qiagen) and 10 pmol of each primer (TIB MOLBIOL,Berlin, Germany). The final concentration of MgCl2 was
4 mM for Asp299Gly, 1.5 mM for Thr399Ile, and 3 mM
for Arg753Gln and Arg677Trp. The PCR was executed
with an initial denaturation step (94°C for 15 min), 35
cycles (94°C for 30 s, 62°C (Asp299Gly), 60°C (Thr399Ile),
or 65°C (Arg677Trp and Arg753Gln) for 30 s, 72°C for
30 s), and a final extension step (72°C for 10 min).
The restriction assay contained 1x restriction buffer, 7.5
units of the respective restriction enzyme (New England
Biolabs, Beverly, MD, USA) and 10 μl of the PCR product.
It was incubated overnight at 37°C and 60°C respectively
and analysed by electrophoresis on a 2.5% agarose gel. Full
length PCR products were digested into the restriction
fragments as listed in Table 3.Statistical analysis
Mann–Whitney U test was used to compare data of
healthy controls and JIA patients, respectively SLE pa-
tients. Kruskal Wallis test was used to compare data of
JIA subtypes. The allele frequencies were calculated
from the numbers of genotypes observed. The signifi-
cance of differences in the allele frequencies among pa-
tients and control subjects was determined by Fischer’s
exact test. χ2 analysis was used to test for deviation of
genotype distribution from Hardy–Weinberg equilib-
rium and for comparison of differences in genotype
combinations among patients and control subjects. Only
the values of p < 0.05 were considered to be statistically
significant in all analyses. Statistical analysis was performed
with commercial software (SPSS Statistics Software version
15.0; SPSS Inc.).Results
TLR2- and TLR4-surface expression
We examined the presence of TLR2 and TLR4 proteins
on peripheral CD14+ blood monocytes of 65 JIA patients
[(19 patients with systemic JIA (3 children under flare),
28 patients with oligoarthritis (3 children under flare), 9
patients with seronegative polyarthritis (3 children under
flare) and 11 patients with enthesitis related arthritis (3
children under flare)] and 9 SLE patients (1 patient
under flare) as well as 67 healthy individuals by flow
cytometry analysis.
We stated that monocytes expressed both TLR2 and
TLR4 molecules, and expression of surface TLR2 was
generally higher than TLR4 level (Figure 1). We ob-
served no significant difference in the levels of TLR 2
expression, as measured by the dMFI, on the monocytes
of JIA and SLE patients (median dMFI, 25.6, minimum
dMFI 10, maximum dMFI 75) compared with the
healthy control subjects (median dMFI 27.5, minimum
dMFI 1.5, maximum dMFI 65.2; p = 0.239; Figure 2a).
Table 2 Sequences of primers used for PCR
Gene and polymorphism Primer 5′-3′ Annealing temperature [°C]
TLR2 Arg677Trp Forward: ccc ctt caa gtt gtg Gct tca taa g 65
TLR2 Arg677Trp Reverse: agt cca gtt cat act tgc acc ac
TLR2 Arg753Gln Forward: cat tcc cca gcg ctt ctg caa gct Cc 65
TLR2 Arg753Gln Reverse:: gga acc tag gac ttt atc gca gct c
TLR4 Asp299Gly Forward: agc ata ctt aga cta cta Cct cca tg 62
TLR4 Asp299Gly Reverse: aga aga ttt gag ttt caa tgt ggg
TLR4 Thr399Ile Forward: ggt tgc tgt tct caa agt gat ttt ggg aGa a 60
TLR4 Thr399Ile Reverse: gga aat cca gat gtt cta gtt gtt cta agc c
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of TLR 4 expression on the monocytes of JIA and SLE pa-
tients (median dMFI, 1.3, minimum dMFI −20.6, maximum
dMFI 97.1) compared with the healthy control subjects
(median dMFI 13.5, minimum dMFI −16.4, maximum
dMFI 99.9; p ≤ 0.001). Especially patients with enthesitis re-
lated arthritis (p ≤ 0.001), oligoarthritis (p = 0.010) and SLE
(p = 0.048) showed significant reduction in the expression
levels of TLR 4 compared with the control group
(Figure 2b). Patients in acute flare showed no significant
change in surface expression levels of TLR 2 (p = 0.299)
and TLR 4 (p = 0.318) compared to patients in remission
(Figure 3).Genotyping of Toll-like receptor-2 and −4 genes
Determination of the TLR 2 (Arg677Trp and Arg753Gln)
and 4 gene mutations (Asp299Gly and Thr399Ile) was ac-
complished with PCR and restriction fragment length
polymorphism (Figure 4). In the present study compared
the allele frequency and genotype distribution for these
mutations among JIA respectively SLE patients and
healthy control subjects.
Regarding the TLR 2 gene, the frequency of the
Arg753Gln mutant allele was 1.3% (1/76) for patients
and 9.0% (6/67) for healthy controls (p = 0.051). Except
for one SLE patient, who was heterozygous for the
Arg753Gln SNP, all the investigated subjects were wild-Table 3 Restriction enzymes and length of the restriction frag








(rs4986791)type for the TLR 2 gene. The Arg677Trp mutant allele
was not found in any of the JIA/SLE patients or healthy
control subjects. None of the study subjects or control
group showed homozygosity for the Toll-like receptor-2
and TLR-4 mutant alleles. Within the group of JIA pa-
tients, the allele frequency of the Asp299Gly mutation
was 6.0% (4/67), the one for the Thre399Ile mutation
was 3.0% (2/67). In comparison, the one in the control
group was 9.0% (6/67) for the Asp299Gly mutant allele
(p = 0.516) and 12% (8/67) for the Thre399Ile mutant al-
lele (p = 0.114). Cosegregation between the mutant al-
leles of the TLR 4 gene was found in 3.0% among JIA
patients and in 9.0% of healthy control subjects. There
was no correlation between the TLR 2 or TLR 4 geno-
types and the demonstrated differential cell surface
expression.Discussion
The stimulation of various TLRs via pathogen-associated
molecular patterns (PAMPs) and damage-associated mo-
lecular patterns (DAMPs) is considered to be the basis
for the emergence of individual autoimmune diseases
such as rheumatoid arthritis [7,8]. The present study re-
veals selective alterations in the expression of Toll-like
receptors 2 and 4 on CD14+ monocytes in the systemic
circulation of patients with JIA and SLE compared to
healthy control subjects. Detectable differences inments
iction temperature [°C] Fragment length [bp]
60°C Wild type (allele C): 130 bp + 22 bp
Arg677Trp (allele T): 152 bp
37°C Wild type (allele G): 104 bp + 25 bp
Arg753Gln (allele A): 129 bp
37°C Wild type (allele A): 188 bp
Asp299Gly (allele G): 168 bp + 20 bp
37°C Wild type (allele C): 124 bp
Thr399Ile (allele T): 98 bp + 26 bp
(a)
(b)
M1 = Median TLR2 –Median Isotypecontrol FITC
=   37.18-7.99
=   29.19
=  delta MFI  TLR2
M1 = Median TLR4 –Median Isotypecontrol PE
=   28.13-25.03
=     3.10
=  delta MFI  TLR4
Figure 1 Representative flow cytometry histograms showing (a) TLR2 and (b) TLR4 expression on CD14+ monocytes. Blue filled
histograms: isotype controls and green or red filled histogram TLR expression. Mean channel fluorescence intensity (MFI) derived from
fluorescence histogram was used to study the level of cell surface TLR expression. Delta MFI (dMFI) was calculated as a subtraction and recorded
as the MFI of the TLR2 or TLR4 antibody minus the MFI of the isotype-matched control antibody.
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volvement of TLRs in the pathogenesis of JIA and SLE.
In the course of this study we demonstrated a signifi-
cantly reduced level of cell surface TLR 4 protein expres-
sion on CD14+ monocytes compared with that of healthy
control subjects. This finding supports the proposed role
of TLR activation by microbial products or their PAMPS
respectively DAMPs in the pathogenesis of JIA and SLE:
TLR stimulation via endogenous and exogenous ligands
may induce the internalization of the respective TLR and
may result in the downregulation of cell surface TLR ex-
pression [22-24]. Former studies on in vitro and in vivo
LPS stimulation demonstrated downregulation of TLR 2
and TLR 4 cell surface expression on human peripheral
blood neutrophils and monocytes [25-27].In particular, the constantly reduced TLR 4 surface
protein levels during active and inactive disease phases
compared with healthy individuals are further evidence
supporting a pathogenetic role of PAMPs, DAMPs and
TLRs in the development of JIA or SLE. The stability of
TLR surface expression in the investigated stages of the
disease could be an expression of a permanent lowering
of TLR 4, but need not necessarily be accompanied by a
loss of receptor function [28].
In a recent study with fibroblast-like synovial cells,
high levels of TLR 2 and TLR 4 messenger RNA
(mRNA) were detected in JIA patients. Furthermore, the
stimulatory effect of bacterial, viral and endogenous TLR
ligands on the production of destructive acting cytokines
IL-6, IL-8 and matrixmetalloproteinases-1 and −3 was
(a)
(b)
Figure 2 (a) Mean fluorescence intensity (dMFI) of TLR2-expression on CD14+ monocytes of patients with JIA, SLE and healthy controls.
(b) Mean fluorescence intensity (dMFI) of TLR4-expression on CD14+ monocytes of patients with JIA, SLE and healthy controls.
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studies on TLR surface expression on monocytes from
sepsis patients suggest that increased TLR-mRNA con-
centrations not necessarily with increased amounts of
cell surface protein. Although LPS causes a heightened
transcription of TLR 2- and TLR 4-messenger RNA inmonocytes, only the TLR 2 surface expression but not
the TLR 4 expression appears to correlate with the TLR-
mRNA concentration [25,27].
The systemic circulation of JIA, RA and SLE patients
likely abounds with endogenous and exogenous TLR2-
and TLR4 ligands, leading to receptor activation and
(a)
(b)
Figure 3 (a) Mean fluorescence intensity (dMFI) of TLR2-expression on CD14+ monocytes of patients in various disease phases
compared to TLR2-expression on monocytes of healthy controls. (b) Mean fluorescence intensity (dMFI) of TLR4-expression on CD14+
monocytes of patients in various disease phases compared to TLR4-expression on monocytes of healthy controls.
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and enzymes can, in turn, affect the TLR activation. In
particular, the proinflammatory cytokines IL-6 and TNF-α
appear to have a LPS-like effect on the TLR4-expression
of human monocytes. While TNF-α inhibits TLR-mRNA
formation and the TLR 4-receptor expression, IL-6 causes
the opposite effect [30]. Moreover the anti-inflammatory
cytokine IL-10 can reduce the concentration of TLR4-
mRNA in monocytes of healthy individuals [31].From our former studies we know, that JIA patients
show compared to healthy subjects significantly higher
levels of proinflammatory cytokines. Furthermore, we
observed higher concentrations of the anti-inflammatory
cytokine IL-10 in patients with oligoarthritis, seronega-
tive polyarthritis and enthesitis related arthritis com-
pared to healthy subjects (unpublished data).
TLR2 and TLR4 genotypes of patients with JIA and SLE
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Figure 4 Electrophoretic separation of TLR2 and TLR4 gene PCR fragments after restriction endonuclease cleavage on agarose gel
(a-d): (a) Agarose gel electrophoresis of the TLR2 Arg677Trp polymorphism (TLR2_C2180T): lane 1, restriction fragments in case of 1
wildtype individual; lane 3, 100 bp DNA ladder; lane 2, PCR product without (before) restriction. (b) Agarose gel electrophoresis of the
TLR2 Arg753Gln polymorphism (TLR2_G2408A): lane 1, 100 bp DNA ladder; lanes 2 and 3, restriction fragments in case of two wildtype
individuals; lane 4 individual heterozygous for the Arg753Gln mutation. (c) Agarose gel electrophoresis of the TLR4 Asp299Gly polymorphism
(TLR4_A1287T): lane 1, 100 bp DNA ladder; lane 2 restriction fragments in case of an individual heterozygous for the Asp299Gly mutation; lane 3,
restriction fragments in case of 1 wildtype individual. (d) Agarose gel electrophoresis of the TLR4 Thr399Ile polymorphism (TLR4_C13174T): lanes
1 and 3, restriction fragments in case of 2 wildtype individuals; lanes 2 and 4, restriction fragments in case of two individuals heterozygous for the
Thr399Ile mutation; lane 5, 100 bp DNA ladder.
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due to any of the reported functional polymorphisms in
these TLR genes [20,32,33]. These polymorphisms have
been associated as well with several autoinflammatory dis-
eases, such as rheumatoid arthritis, as well as with the sus-
ceptibility to bacterial infections [34-36]. Especially the
Asp299Gly SNP of TLR 4 has been shown to correlate
positively with an endotoxin hyporesponsive phenotype in
humans [20,32]. Interestingly, within the group of JIA pa-
tients the allele frequency of the Asp299Gly mutation was
only 6.0% (4/67) compared with an allele frequency of
9.0% (6/67) within the control group (p = 0.516). The
Arg753Gln polymorphism of the TLR2 gene also has been
reported to be of pathogenetic significance [33]. However,except for one SLE patient, who was heterozygous for the
Arg753Gln SNP, all the investigated subjects were wild-
type for the TLR2 gene. This finding indicates that the ob-
served reduced TLR4 protein expression on monocytes of
JIA and SLE patients is not due to a known functional SNP
in the TLR4 gene, but instead, it is supportive of a kind of
tolerance to PAMPs and cellular danger signals. This toler-
ance may result from former activation of TLR4 signaling
pathway by recent exposure to microbial or endogenous li-
gands. Hence, these results do not confirm a significant role
of the described SNPs in the TLR genes in the observed dif-
ferential TLR protein expression levels on monocytes from
patients with JIA and SLE, compared with that in healthy
individuals.
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To conclude, our observations suggest involvement of
investigated TLRs in the pathogenesis of JIA and SLE. It
still remains to be elucidated whether reduced TLR4 ex-
pression is cause of chronic arthritis or a result of some
feedback loop.
Although the results of this study for surface expression
of TLR2 and TLR4 within JIA and SLE patients differ, in
some aspects, from the results of other studies, they do
not necessarily contradict them. In our own experiments
(unpublished data) we have shown that the technical im-
plementation affects the density of TLRs on monocytes
significantly: Unstimulated monocytes expressed TLR2,
TLR4, and CD14 in whole blood with an identical pattern
to that seen in purified peripheral blood mononuclear
cells (PBMC), although with lower mean fluorescences
than were seen in purified cells. After stimulation with
Lipopolysaccharid (TLR4) or Zymosan (TLR2) in whole
blood we observed the expected increase of TLR2 respect-
ively TLR4 on monocytes. In contrast, in purified PBMC
populations we found as a result of Zymosan stimulation
a significant decrease of TLR2 density (dMFI unstimu-
lated: median 100, dMFI stimulated: median −400) and an
increase of TLR4 density (dMFI unstimulated: median 30,
dMFI stimulated: median 600) on monocytes.
Additional studies of TLR-mRNA expression in mono-
cytes of these patients could possibly confirm a negative
correlation with respect to the amount of TLR4 protein
and TLR4-mRNA concentration. Further experiments
with TLR antagonists may help to evaluate the cytokine
network activated by TLRs.Competing interests
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